Rao SV, Kirsch B, Bhatt DL, Budaj A, et al. A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes Following Acute Myocardial Infarction. Circulation 2022 Aug 27. doi: 10.1161/CIRCULATIONAHA.122.061612.
PMID: 36030390